Singapore, July 17 -- Canada-based ExCellThera Inc., a global leader in blood stem cell expansion and metabolic fitness technologies and parent company of Cordex Biologics, has announced that Cordex has entered into an agreement granting FarmaMondo SA distribution rights for Zemcelpro(R) (dorocubicel), also known as UM171 Cell Therapy, in Argentina, Hong Kong and Singapore.

Zemcelpro(R) is a novel personalised cryopreserved hematopoietic stem cell transplantation product containing two cellular components: UM171-expanded CD34+ cells (dorocubicel); and unexpanded CD34- cells, each derived from the same cord blood unit. It is indicated in the European Union for the treatment of adult patients with hematological malignancies requiring allog...